Global Rare disease Market, By Drug Type (Biologics and Non-biologics),By Route of Administration (Oral and Injectable), By Phase (Preclinical, Phase1, Phase2, Phase3, Phase4), By Therapeutic Area (Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others), By Patients (Neonatal, Pediatric, Adult), By Distribution Channel (Hospital & Retail Pharmacies, e-Commerce/Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI463421 | Publish Date: April 2023 | No. of Pages: 168

Global Rare Disease Market Overview

Genetic and Rare Diseases (GARD) has information from the Food and Drug Administration (FDA) on treatments approved for rare diseases, known as orphan products/drugs. The Orphan Drug Act was passed in 1983 to give drug companies incentives to develop treatments for rare disease. Most rare diseases are genetic thus present throughout the person's entire life, even if symptoms do not immediately appear. Many rare diseases appears early in life, and about 30% of children with rare diseases dies before reaching their fifth birthday. With only three diagnosed patients since 27 years, ribose-5-phosphate isomerase deficiency is considered the rarest known genetic disease. The Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR 13.1%.

 

Impact of Covid-19 pandemic on market

The recent coronavirus outbreak has instilled panic among people all across the world. Rapidly spread of the disease in several countries, strict measures have been taken to curb the epidemic. Moreover, governments across the world are implementing strategies and raising funds that will result in more attention towards the treatment of the coronavirus disease. This has indirectly halted the rare disease market. This pandemic has certainly left manufacturers in a state of confusion. Given the current situation, the market is set to be negatively affected by this pandemic.

Global Rare Disease Market Dynamics

Rising research activities and development of novel drugs

Increasing research activities and development of rare disease drugs has driven the global rare disease market. Additionally, growing product development and implementation of technology drive the innovative devices in diagnosis of which leads to increase adaption of effective treatment of rare disease.

Many key players globally are coming forward

For meeting the needs of the minority patients, local and multi-national market players are modifying their overall clinical operating models and alignment strategies for the sustainability of the newly developed market. An important parameter that is estimated to be playing a pivotal role in the overall establishment and growth of the rare disease market is the accelerated rate at which advancement is taking place in medical science and technology.

Lack of awareness regarding rare diseases

Many rare diseases go undiagnosed for span of time because families, patients and physicians may have limited awareness of certain diseases, and the symptoms may not be informative to healthcare workers who may not have encountered such diseases before. However, technical and clinical-related challenges might hamper growth of the global market to a certain extent.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Rare Disease Market Segmentation

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Rare Disease Market is segmented based on drug type, route of administration, phase, therapeutic area, patients, distribution channel and region.

By Drug type, Global Rare Disease Market is segmented into Biologics and Non-Biologics. By Route of Administration, Global Rare Disease Market is segmented into Oral and Injectable. By Phase, Global Rare Disease Market is segmented into Preclinical, Phase1, Phase2, Phase3, and Phase4. By Therapeutic Area, Global Rare Disease Market is segmented into Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others. By Therapeutic Area, Global Rare Disease Market is segmented into Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others. By Patients, the market is segmented in Neonatal, Pediatric, and Adults. By Distribution Channel, Global Rare Disease Market is segmented into Hospital & Retail Pharmacies and E-commerce/Online Pharmacies.

Regional Insights:

 

On region the Global Rare Disease Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominating the rare disease market due to increase spending in R&D by major companies to aid the growth of this market. The increase demand for the product in the United States as well as Canada will also contribute to the growth of the market in the coming years. Europe’s market will derive growth from the adoption of technologically advanced manufacturing equipment by major companies in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation
  • By Drug type- Biologics and Non-Biologics.
  • By Route of Administration- Oral and Injectable.
  • By Phase- Preclinical, Phase1, Phase2, Phase3, Phase4.
  • By Therapeutic Area- Infectious disease, Neurological, Alimentary/Metabolic, Cancer, Blood & Clotting and Others.
  • By Patients- Neonatal, Pediatric, Adults.
  • By Distribution Channel- Hospital & Retail Pharmacies, and E-commerce/Online Pharmacies.

 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global rare market is segmented into drug type, route of administration, phase, therapeutic area, patients, distribution channel and region.

 

 

Global Rare Disease Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Rare Disease Market Key Players

The key players operating in the Global Rare Disease Market includes Hoffmenn-La Roche, Abbott, Pfizer, Sanofi, Eli Lilly, Genelux, Mercks & co., Glaxosmith Kline, Astra Zeneca, Eisai, Rexahn and Taino. On 25th September 2020, AstraZeneca, and Daiichi Sankyo Company announced that the company had received the FDA Orphan Drug Designation for their product offering of Enhertu (trastuzumab deruxtecan) for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Global Rare Disease Market Company Profile

  • Pfizer
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hoffmen La Roche
  • Abbott
  • Sanofi
  • Eli lilly
  • Genelux
  • Mercks & co.
  • Glaxosmith Kline
  • Astra Zeneca
  • Eisai
  • Rexahn
  • Taino                                                                                                                                                                                                                                                                                                                                                                                                  “*” marked represents similar segmentation in other categories in the respective section

Global Rare Disease Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Rare Disease Market strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Phase
      • Market Snippet, By Therapeutic Area
      • Market Snippet, By Patients
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Rare Disease Market, By Drug Type 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Biologics
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Non-Biologics
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Rare Disease Market, By Route of Administration 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Injectable
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Rare Disease Market, By Phase, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Preclinical
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Phase1
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Phase2
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Phase3
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Phase4
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global Rare Disease Market, By Therapeutic Area, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Infectious Disease
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Neurological
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Alimentary/Metabolic
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Blood & Clotting
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  2. Global Rare Disease Market, By Patients, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Neonatal
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Pediatric
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Adults
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  3. Global Rare Disease Market, By Distribution Channel, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital & Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • E-Commerce/Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  4. Global Rare Disease Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Phase, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic Area, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
      •  – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Phase, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic Area, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Phase, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic Area, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Phase, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic Area, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Phase, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Therapeutic Area, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  5. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  6. Company Profiles
  • Pfizer
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hoffmann-La Roche
  • Abbott
  • Sanofi
  • Eli Lilly
  • Genelux
  • Mercks & co.
  • Glaxosmith Kline
  • Astra Zeneca
  • Eisai
  • Rexahn
  • Taino
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The Global Rare Disease Market is segmented based on drug type, route of administration, phase, therapeutic area, patients, distribution channel and region.

Rising awareness by government bodies and coming up with new technologies is the major factor driving growth of the global market

North America is expected to lead the market due to increase spending in Research and Drug by major companies.

Companies are continuously rising the production and supply of orphan drugs.